Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285864 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL1110071 | 1.00 | KDM4E (0.38) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL25093174 | 0.98 | KDM4E (0.37) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL10017901 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL863457 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL12717539 | 0.93 | KDM4E (0.39) | KDM4EALDH1A1DRD2DRD3LMNA | |
| SCHEMBL738020 | 0.83 | — | — | |
| SCHEMBL463379 | 0.83 | — | — | |
| SCHEMBL738505 | 0.83 | — | — | |
| SCHEMBL14818612 | 0.83 | KDM4E (0.33) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | VYOME THERAPEUTICS LIMITED (IN) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570152-B2 | Antibacterial therapeutics and prophylactics | CLPP, CFTR, ELANE | KDM4E 4759/4885ALDH1A1 4010/4885DRD2 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.